There is no significant correlation of adenomyosis with benign, premalignant and malignant gynecological pathologies. Retrospective study on 647 specimens

article OA: gold CC0 ⤵ 4 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-07

This retrospective study of 647 specimens found no significant correlation between adenomyosis and the prevalence of benign, premalignant, or malignant gynecological pathologies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07

This retrospective study reviewed histologically confirmed adenomyosis in 647 women undergoing gynecological surgery (1985–2020 across two hospitals), recording concurrent FIGO-classified benign, premalignant, and malignant gynecologic conditions. Adenomyosis coexisted with at least one other gynecologic pathology in 81.5% of cases, with the most common coexisting findings being uterine leiomyomas (61.3%), endometrial polyps (11.9%), endometriosis (11.6%), and endometrial hyperplasia (7.1%); among malignancies, endometrial cancer occurred in 3.6%, ovarian cancer in 1.4%, and cervical cancer in 0.8%. The authors report no significant correlation between adenomyosis prevalence and benign, premalignant, or malignant disease categories compared with the general population, while noting that the study design centers on surgical/previously selected patients and relies on postoperative histology. This paper is centrally about adenomyosis — evaluating whether adenomyosis correlates with other gynecologic benign, premalignant, and malignant pathologies and reporting a co-occurrence rate with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVES: The aim of this study is to identify the prevalence of benign, premalignant and malignant gynecological pathologies in women with adenomyosis who underwent gynecological surgery. MATERIAL AND METHODS: The medical records collected between 1985 and 2020 were retrospectively reviewed. The pathology reports were studied from 647 cases where adenomyosis was presented. The estimated prevalence of benign, premalignant and malignant gynecological disorders in the general population was further evaluated. RESULTS: The mean age of women with adenomyosis was 54.1 ± 10.4 years old. Out of 647 patients, in 18.5% of the specimens we detected isolated adenomyosis and in 81.5% of cases a coexistence of one or more gynecological diseases, while in 84 out of 647 patients (13%) there was coexistence of adenomyosis with more than one gynecological condition (benign or malignancy). Among all cases, uterine leiomyomas were observed in 61.3% of patients, followed by endometrial polyps (11.9%), endometriosis (11.6%), endometrial hyperplasia (7.1%), endometrial cancer (3.6%), ovarian (1.4%) and cervical cancer (0.8%) (p < 0.001).Additionally, we found that women with a simultaneous co-existence of adenomyosis, leiomyomas and endometrial polyps or hyperplasia were younger (p < 0.01) in comparison to cases with malignancy. CONCLUSIONS: Adenomyosis presents a common benign but often progressing myometrial condition that it is underestimated in clinical practice. Even though some studies suggest a potential association with several gynecological pathologies, we did not confirm a significant difference of adenomyosis prevalence between benign, premalignant and malignant gynecological conditions compared with the general population. Further investigation is required to confirm our results.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisadenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Endometriosis Endometriosis Genital Diseases, Female Leiomyoma Leiomyoma Precancerous Conditions Precancerous Conditions Uterine Neoplasms Uterine Neoplasms Uterine Neoplasms Adult Female Humans Middle Aged Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:03.506079+00:00
License: CC0 · commercial use OK